- $13.72m
- $40.07m
- $3.00m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.58 | ||
| EV to EBITDA | 1.64 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | 776.79% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.5 | 0.38 | 2.45 | 3 | 0.2 | 1.13 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
Directors
- Lishan Aklog CHM (55)
- Dennis Mcgrath PRE (64)
- Michael Glennon VCH (54)
- Brian DeGuzman OTH (56)
- Tim Baxter DRC (60)
- Debra White DRC
- James Cox IND (77)
- Ronald Sparks IND (65)
- David Weild IND (64)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 26th, 2014
- Public Since
- July 27th, 2016
- No. of Shareholders
- 227
- No. of Employees
- 39
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 17,368,034
- Address
- 360 Madison Avenue, 25Th Floor, NEW YORK, 10017
- Web
- https://pavmed.com/
- Phone
- +1 2129494319
- Contact
- Matt Riley
- Auditors
- Marcum LLP
Upcoming Events for PAVM
Q1 2025 PAVmed Inc Earnings Call
PAVmed Inc Annual Shareholders Meeting
PAVmed Inc Annual Shareholders Meeting
Q2 2025 PAVmed Inc Earnings Release
Similar to PAVM
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the PAVmed share price?
As of Today at 22:35 UTC, shares in PAVmed are trading at $0.79. This share price information is delayed by 15 minutes.
How has the PAVmed share price performed this year?
Shares in PAVmed last closed at $0.79 and the price had moved by -64.73% over the past 365 days. In terms of relative price strength the PAVmed share price has underperformed the S&P500 Index by -68.19% over the past year.
What are the analyst and broker recommendations for PAVmed?
The overall consensus recommendation for PAVmed is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the PAVmed dividend yield?
PAVmed does not currently pay a dividend.
Does PAVmed pay a dividend?
PAVmed does not currently pay a dividend.
When does PAVmed next pay dividends?
PAVmed does not currently pay a dividend.
How do I buy PAVmed shares?
To buy shares in PAVmed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of PAVmed?
As of the previous close price of $0.79, shares in PAVmed had a market capitalisation of $13.72m.
Where are PAVmed shares listed?
Here are the trading details for PAVmed:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PAVM
What kind of share is PAVmed?
Based on an overall assessment of its quality, value and momentum PAVmed is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a PAVmed share price forecast for 2025?
The analyst consensus target price for shares in PAVmed is $11.75. That is 1387.15% above the last closing price of $0.79.
Analysts covering PAVmed currently have a consensus Earnings Per Share (EPS) forecast of -$0.57 for the next financial year.
Find out moreWhat is the trend in the PAVmed share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PAVmed. Over the past six months, its share price has underperformed the S&P500 Index by -22.72%.
As of the last closing price of $0.79, shares in PAVmed were trading -10.75% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the PAVmed PE Ratio?
The PAVmed PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.79.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of PAVmed?
PAVmed's management team is headed by:
- Lishan Aklog - CHM
- Dennis Mcgrath - PRE
- Michael Glennon - VCH
- Brian DeGuzman - OTH
- Tim Baxter - DRC
- Debra White - DRC
- James Cox - IND
- Ronald Sparks - IND
- David Weild - IND